As of 2023, the US FDA has approved 72 small molecule therapeutic protein kinase inhibitors for cancer.37 There are 57 anti-solid tumor drugs.37 For example, Imatinib (Glivec), as the first small molecular inhibitor specifically designed to address the mechanisms of tumor formation, has heralded a new epoch in cancer therapy with its successful development and application. This evidence concerns the gene WEE1 and cancer.